Izraelská lékařská výzkumná společnost hledá partnery pro vývoj nových tkáňových náhrad

Izraelská lékařská výzkumná a vývojová společnost vyvinula první biochemické inovace pro růst kožní tkáně. Společnost hledá výzkumné a vývojové partnery ke spolupráci na rozvoji bezpečných a efektivních metod náhrad kožních tkání.

An Israeli medical R&D company has developed the first biochemical innovation to induce dermal-tissue growth in skin-deficient patients. The company seeks international R&D partners to cooperate in developing safe, efficient, inexpensive skin-patch technology. The patch, similar to immunization patches, is the only biochemical skin-growth option, as it naturally induces tissue expansion by emitting elastase through painless micro-needles, deactivating skin’s elastin.

Skin is comprised of two main fibers in the dermal layer: collagen, which provides strength in skin, and elastin fibers, which provide elasticity, acting like "springs" that prevent expansion. The innovative technology induces specific breakdown of elastin fibers by emitting natural elastase through microscopic needles on a topical patch, thus causing extra skin to grow with minimal tightness, traction (pulling) force, or scar.

In general, skin tissue expansion is a straightforward mechanical procedure that enables the body to "grow" extra skin. The procedure is used for patients suffering skin cancer, breast cancer, trauma or malady that requires skin reconstruction. Currently, there are three main options for skin-deficient patients, all with their risks and aesthetic disadvantages:
1. Skin Grafting: Health-safety risks are high if the patient does not have the correct blood supply or blood pressure. Skin grafting surgery is costly, since only very skilled professionals can perform a graft. Aesthetically, scars are inevitable both from the donor site as well as the grafted site. Finally, a graft takes at least a few days to adhere, and the end result looks like a mismatched patch.
2. Skin-Expanders and Skin-Stretch Devices: The procedure constitutes surgical, mechanical overstretch, by inserting an inflatable expander into the skin, and repeatedly injecting saline over a few weeks to slowly stretch overlaying skin. While skin that grows as a result of surgery is permanent, it will inevitably retract or scar when the inflatable expander is removed, causing pain and obvious marks where the surgery occurred.
3. Micro-Surgery: An expensive, long procedure, only performed by skilled staff, often unaffordable to patients in need.

Unlike today’s most common skin-expansion procedures, the Israeli company’s innovation is a safe patch that works in conjunction with the body's natural skin expansion technique. Its micro-needle intra-dermal delivery is a proven method of immunization in children. The patch will be placed on normal skin immediately next to the deficit area, to insure an aesthetic result because skin that grows will match normal skin.

Skin-growth through elastase emission have been proven in various cases and experiments. The medical experts at this Israeli company researched Cutis-Laxa patients, born producing excess skin because of elastase over-activity. While Cutis-Laxa patients undergo surgery to excise their excess skin, their condition provides scientific basis for the Israeli company to develop technology based on the body’s natural method of skin expansion.

Some advantages to the micro-needle elastase patch is that it is cost-efficient, time-efficient (requires less than 2 hours to treat skin), can be self-administered, and provides a more aesthetic outcome than other methods of skin expansion.

The technology is the first of its kind, and will change the lives of millions of patients unfortunately required to undergo skin reconstruction after malady and trauma.
Technical Specifications / Specific technical requirements of the request

The company seeks additional partners who:
1. supply human recombinant elastase under GMP standards
2. manufacture and provide micro-needle patches currently used for immunizations (to be utilized for intra-dermal elastase delivery)
Current and Potential Domain of Application

1. Skin-cancer, breast-cancer patients, patients requiring skin reconstruction.
2. In the U.S., approx. 3.5 million patients annually diagnosed with skin-cancer. Based on company research, at least 10% of patients would opt for patch.
3. Trauma, burns, aesthetic surgeries, hair transplantation.

List of Keywords
Technology

* Medicine, Human Health
* Medical Technology / Biomedical Engineering

Market
Collaboration Type

* Joint further development


Comments
- Type of partner sought: International R&D, Medical supply company, Chemical supply company

- Specific area of activity of the partner: Supply human recombinant elastase; manufacture and provide intra-dermal patches for immunizations

- Task to be performed by the partner sought: Further develop and expand this technology


Ref: 12 IL 80EP 3OFX

www.inovace.cz